Related Experiment Videos
Diagnosing nontuberculous mycobacterial lung disease. A process in evolution
David E Griffith1, Barbara A Brown-Elliott, Richard J Wallace
1Clinical Tuberculosis Services, University of Texas Health Center, Tyler, Texas, USA. david.griffith@uthct.edu
Infectious Disease Clinics of North America
|March 29, 2002
Summary
Diagnosing nontuberculous mycobacterial (NTM) lung disease is now common, but deciding on appropriate treatment remains a challenge. The focus has shifted from diagnosis to determining the necessity and potential harm of therapies for NTM lung disease.
Area of Science:
- Pulmonology
- Infectious Diseases
- Clinical Medicine
Background:
- Nontuberculous mycobacterial (NTM) lung disease diagnosis has advanced significantly.
- Historically, NTM disease was often unrecognized and untreated, leading to progressive illness.
- Current challenges involve managing frequently diagnosed NTM cases where treatment may be unnecessary or detrimental.
Purpose of the Study:
- To highlight the diagnostic advancements in NTM lung disease.
- To address the critical issue of therapeutic decision-making post-NTM diagnosis.
- To re-evaluate the necessity and potential risks associated with NTM lung disease treatments.
Main Methods:
- Review of historical and current approaches to NTM lung disease diagnosis.
- Analysis of treatment paradigms and their impact on patient outcomes.
- Consideration of expert guidelines and clinical consensus on NTM management.
Main Results:
- Frequent diagnosis of NTM lung disease is now achievable.
- Therapeutic interventions for NTM lung disease are not always indicated.
- The risks associated with NTM treatment may outweigh the benefits in some cases.
Conclusions:
- The primary challenge in NTM lung disease is no longer diagnosis but therapeutic strategy.
- Healthcare professionals must carefully weigh the risks and benefits of treatment for each patient.
- Revisiting earlier clinical recommendations may be warranted in managing NTM lung disease.